• 1
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 2
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
  • 3
    Thiesse P, Olliver L, Di Stefano-Louineau D, et al. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 1997; 15: 3507-3514.
  • 4
    Padhani AR, Husband JE. Are current tumor response criteria relevant for the 21st century? Br J Radiol. 2000; 73: 1031-1033.
  • 5
    Belton AL, Saini S, Liebermann K, et al. Tumor size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol. 2003; 58: 311-314.
  • 6
    Husband JE, Schwartz LH, Spencer J, et al. Evaluation of the response to treatment of solid tumours—a consensus statement of the International Cancer Imaging Society. Br J Cancer. 2004; 90: 2256-2260.
  • 7
    Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004; 22: 4442-4445.
  • 8
    Schuetze SM. Imaging and response in soft tissue sarcomas. Hematol Oncol Clin North Am. 2005; 19: 471-487.
  • 9
    Curran SD, Muellner AU, Schwartz LH. Imaging response assessment in oncology. Cancer Imaging. 2006; 6: S126-S130.
  • 10
    Jaffe CC. Measures of response: RECIST, who and new alternatives. J Clin Oncol. 2006; 24: 3245-3251.
  • 11
    Gwyther SJ, Schwartz LH. How to assess anti-tumor efficacy by imaging techniques. Eur J Cancer. 2008; 44: 39-45.
  • 12
    Therasse P, Eisenhauer EA, Buyse M. Update in methodology and conduct of cancer clinical trials. Eur J Cancer. 2006; 42: 1322-1330.
  • 13
    Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal carcinoma. J Clin Oncol. 2006; 24: 2505-2512.
  • 14
    Mortzer RJ, Michealson D, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24.
  • 15
    Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011; 55: 1309-1316.
  • 16
    Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by RECIST and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012; 118: 147-156.
  • 17
    Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol. 2012; 47: 11-17.
  • 18
    Morgan B. Opportunities and pitfalls of cancer imaging in clinical trials. Nat Rev Clin Oncol. 2011; 8: 517-527.
  • 19
    Lassau N, Koscielny S, Chami L, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification—preliminary results. Radiology. 2011; 258: 291-300.
  • 20
    Lassau N, Koscielny S, Albiges L, et al. Metastatic renal cell carcinoma treated with sunitinib: early contrast-enhanced ultrasonography evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res. 2010; 16: 1216-1225.
  • 21
    Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50( suppl 1): 122S-150S.
  • 22
    Choi H, Charnsangavej C, Faria SC, at al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753-1759.
  • 23
    Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007; 25: 1760-1764.
  • 24
    Grosso F, Joner RL, Demetri G, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8: 595-602.
  • 25
    Gronchi A, Bui BN, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012; 23: 771-776.
  • 26
    Holscher HC, Hermans J, Nooy MA, et al. Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma? Skeletal Radiol. 1996; 25: 19-24.
  • 27
    Lang P, Wendland M, Saeed M, et al. Osteogenic sarcoma: non-invasive in vivo assessment of tumor necrosis with diffusion weighted MR imaging. Radiology. 1998; 206: 227-235.
  • 28
    Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bone in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol. 2004; 34: 595-605.
  • 29
    Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology. 2009; 251: 447-456.
  • 30
    Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012; 30: 850-856.
  • 31
    Fletcher CDM, Unni KK, Martens F, eds. Pathology and Genetics. Tumors of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
  • 32
    Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley and Sons; 1981.
  • 33
    Zito FA, Verderio P, Simone G, et al. Reproducibility in the diagnosis of needle core biopsies of non-palpable breast lesions: an international study using virtual slides published on the world-wide web. Histopathology. 2010; 56: 720-726.
  • 34
    Landis R, Koch G. The measurement of observer agreement for categorical data. Biometrics. 1977; 33: 117-127.
  • 35
    Kaplan WE, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 36
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187-220.
  • 37
    Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. Chichester, United Kingdom: Wiley; 1995.
  • 38
    Tierney JF. Adjuvant chemotherapy for localized respectable soft-tissue sarcoma of adults: meta-analysis of individual data—Sarcoma Meta-Analysis Collaboration. Lancet. 1997; 350: 1647-1654.
  • 39
    Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcoma of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19: 1238-1247.
  • 40
    Woll PJ, van Glabbeke M, Hohenberger P, et al; EORTC Soft Tissue and Bone Sarcoma Group. Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: Interim analysis of a randomized phase III trial [abstract]. J Clin Oncol. 2007; 25( 18S). Abstract 10008.
  • 41
    Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113: 573-581.